baha the information company

baha is a leading provider of real-time market data, financial news, technology and solutions for the financial industry. baha offers real-time data terminals for professionals, global financial market data covering over 12 million financial instruments on more than 150 exchanges, as well as 24/7 breaking news with global coverage and free web and mobile apps. From a total of around 200 real-time data providers worldwide, only Reuters 1851, Bloomberg 1981 and now baha in 2021 were named after the founder.

Replimune Group/ US76029N1063 /

2024-06-03 9:59:59 PM	Chg. +0.14	Volume	Bid-	Ask-	High	Low
5.43USD	+2.74%	19,895 Turnover: 110,346.16	-Bid Size: -	-Ask Size: -	5.87	5.31

GlobeNewswire 06-03 Replimune Presents Positive Data from RP1 and RP2 Clinical Programs at the 2024 American Society of ...

GlobeNewswire 05-23 Replimune to Present at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

GlobeNewswire 05-16 Replimune Reports Fiscal Fourth Quarter and Year Ended 2024 Financial Results and Provides Corporate...

GlobeNewswire 04-07 Interim Results from the ARTACUS Clinical Trial of RP1 Monotherapy in Solid Organ and Hematopoietic ...

GlobeNewswire 04-04 Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire 03-26 Replimune Announces Appointment of Sushil Patel to CEO and Executive Leadership Transitions

GlobeNewswire 03-06 Replimune to Present at the American Association for Cancer Research Annual Meeting 2024

GlobeNewswire 03-05 Replimune to Present at Three Upcoming Investor Conferences

GlobeNewswire 02-08 Replimune Reports Fiscal Third Quarter 2024 Financial Results and Provides Corporate Update

GlobeNewswire 2023-12-28 Replimune to Present at the 42nd Annual J.P. Morgan Healthcare Conference

GlobeNewswire 2023-12-05 Replimune Shares Initial Primary Analysis Results from CERPASS Clinical Trial in Advanced Cutaneous ...

GlobeNewswire 2023-11-08 Replimune Presents Updated Data on RP2 in Uveal Melanoma during Plenary Session at the 20th Internat...

GlobeNewswire 2023-11-07 Replimune Reports Fiscal Second Quarter 2024 Financial Results and Provides Corporate Update

GlobeNewswire 2023-11-04 Replimune Presents Updated Interim Results from the ARTACUS Clinical Trial of RP1 Monotherapy in Sol...

GlobeNewswire 2023-09-19 Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire 2023-09-19 Replimune Announces Appointment of Emily Hill as Chief Financial Officer

GlobeNewswire 2022-03-21 Replimune to Host Virtual Investor Event on March 30, 2022

GlobeNewswire 2022-02-11 Replimune to Present at the 11th Annual SVB Leerink Global Healthcare Conference

GlobeNewswire 2022-02-03 Replimune Reports Third Fiscal Quarter Financial Results and Provides Corporate Update

GlobeNewswire 2022-01-31 Replimune Announces the Departure of Dr. Otello Stampacchia from its Board of Directors

GlobeNewswire 2022-01-10 Replimune Provides 2021 Year End Review and Overview of Expected 2022 Milestones

GlobeNewswire 2022-01-04 Replimune to Present at the 40th Annual J.P. Morgan Healthcare Conference

GlobeNewswire 2021-12-02 Replimune Appoints Christy Oliger to its Board of Directors

GlobeNewswire 2021-11-12 Replimune Provides Updated Data from RP2 at the 2021 Society for Immunotherapy of Cancer’s (SITC) 36...

GlobeNewswire 2021-11-04 Replimune Reports Fiscal Second Quarter Financial Results and Provides Corporate Update

Replimune Group/ US76029N1063 /

If you wish to receive reply to your feedback, please provide your email address.